Hypofractionated palliative radiotherapy for bladder cancer

Support Care Cancer. 2016 Jan;24(1):181-186. doi: 10.1007/s00520-015-2765-y. Epub 2015 May 16.

Abstract

Purpose: The aim of this study was to evaluate hematuria-free survival as well as acute and late toxicity after hypofractionated palliative radiotherapy for bladder cancer.

Methods and materials: Between September 2004 and January 2013, 44 patients with biopsy-proven urothelial carcinoma of the bladder were irradiated according to a palliative schedule to a total dose of 34.5 Gy in six fractions of 5.75 Gy given once a week.

Results: After a mean follow-up of 10 months, 91% of patients were still hematuria free, with a mean hematuria-free survival of 13 months. Severe (≥ grade 3) acute and late urinary toxicity was observed in 9 and 19% of patients, respectively.

Conclusion: This hypofractionated radiotherapy schedule appears to result in acceptable toxicity and manages successful and long-term palliation of hematuria in most patients.

Keywords: Altered fractionation; Bladder cancer; Palliation; Radiotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Dose Fractionation, Radiation
  • Female
  • Hematuria / urine*
  • Humans
  • Male
  • Middle Aged
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / radiotherapy*